Investment
Features
FeesSafety
Academy
More
Pluang+

Compare YieldMax AI & Tech Portfolio Option Income ETF (GPTY) vs McKesson Corporation (MCK) Price & Performance

YieldMax AI & Tech Portfolio Option Income ETFTrade
McKesson CorporationTrade

Price performance (Past 24H)

Key statistics

YieldMax AI & Tech Portfolio Option Income ETF vs McKesson Corporation — how do they compare? YieldMax AI & Tech Portfolio Option Income ETF trades at $42.99 (market cap $135.69M), while McKesson Corporation trades at $937.1 (market cap $108.46B). The key difference: McKesson Corporation is far larger — about 799.3× YieldMax AI & Tech Portfolio Option Income ETF's market cap, and McKesson Corporation pays a 0.4% dividend while YieldMax AI & Tech Portfolio Option Income ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold YieldMax AI & Tech Portfolio Option Income ETF for 61 Days and McKesson Corporation for 74 Days on average.

GPTYMCK
Market Cap
$135.69M$108.46B
Volume
97,442712,607
Sector
Income / Options OverlayHealth
52-Week High
$50.52$995.69
52-Week Low
$34.73$725.17
Typical Hold Time
61 Days74 Days
Enterprise Value
—$115.00B
Dividend Yield
—0.4%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

YieldMax AI & Tech Portfolio Option Income ETF

No Aura AI signal available yet.

McKesson Corporation

McKesson Corporation (MCK) trades at $938.84, up 3.13% with strong technical momentum and bullish analyst sentiment. The stock shows consistent earnings beats with Q2 2026 EPS of $9.93 exceeding expectations of $9.56. Recent news highlights the extension of McKesson's pharmaceutical distribution agreement with CVS Health through 2032, reinforcing long-term revenue visibility. Revenue growth remains robust, climbing from $264.0B in 2022 to $359.1B in 2025, though net margins are thin at 1.12%.

The outlook is positive with 81% analyst buy ratings and a $956.43 consensus price target. Key risks include margin pressure from drug pricing policies and high current liabilities of $61.60B. The stock's valuation at 24.95x P/E appears reasonable given earnings growth projections, but investors should monitor debt levels and regulatory developments in healthcare distribution.

Returns comparison

Trailing returns across standard periods

Investor sentiment on Pluang

What Pluang investors did over the last 30 days

GPTY
83% Buy17% Sell
Avg holding period · 61 Days
MCK
100% Buy0% Sell
Avg holding period · 74 Days

Top news

Latest headlines on both assets

About YieldMax AI & Tech Portfolio Option Income ETF

GPTY is an actively managed ETF that seeks to provide current income and capital appreciation by holding a concentrated portfolio of 15 to 30 leading AI and technology companies. It utilizes a variety of options strategies, including selling call options on its underlying holdings, to generate weekly distributions while maintaining direct equity exposure to the growth of the AI sector.

Read more on GPTY →

About McKesson Corporation

McKesson is a leading wholesaler of branded, generic, and specialty pharmaceutical products to pharmacies (retail chains, independent, and mail order), hospitals networks, and healthcare providers. Along with AmerisourceBergen and Cardinal Health, the three account for well over 90% of the U.S. pharmaceutical wholesale industry. McKesson is currently divesting from its pharmaceutical wholesale and distribution in Europe and Canada in order to redeploy capital to strategic growth areas in the U.S. (oncology network and ecosystem, and biopharma services). Additionally, the company supplies medical-surgical products and equipment to healthcare facilities and provides a variety of technology solutions for pharmacies.

Read more on MCK →